14 reports of this reaction
1.5% of all NEOSTIGMINE METHYLSULFATE reports
#16 most reported adverse reaction
TACHYCARDIA is the #16 most commonly reported adverse reaction for NEOSTIGMINE METHYLSULFATE, manufactured by Exela Pharma Sciences, LLC. There are 14 FDA adverse event reports linking NEOSTIGMINE METHYLSULFATE to TACHYCARDIA. This represents approximately 1.5% of all 959 adverse event reports for this drug.
Patients taking NEOSTIGMINE METHYLSULFATE who experience tachycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TACHYCARDIA is a less commonly reported adverse event for NEOSTIGMINE METHYLSULFATE, but still significant enough to appear in the safety profile.
In addition to tachycardia, the following adverse reactions have been reported for NEOSTIGMINE METHYLSULFATE:
The following drugs have also been linked to tachycardia in FDA adverse event reports:
TACHYCARDIA has been reported as an adverse event in 14 FDA reports for NEOSTIGMINE METHYLSULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TACHYCARDIA accounts for approximately 1.5% of all adverse event reports for NEOSTIGMINE METHYLSULFATE, making it a notable side effect.
If you experience tachycardia while taking NEOSTIGMINE METHYLSULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.